NEW ORLEANS — A novel plasmid-based immunotherapy was safe and well tolerated among adults with type 1 diabetes autoantibodies, according to phase 1 trial data presented at the American Diabetes Association Scientific Sessions.NNCO361-0041 (Novo Nordisk) is an immunotherapy in which a plasmid acts as a carrier of preproinsulin and three cytokines. It is designed to prevent the immune system from…
Source: Healio News
